Binding Site
July 17th, 2008 — admin
Warstock Road, Kings Heath
B14 4RT Birmingham
United Kingdom
P.O. Box 1 17 12
B14 4ZB Birmingham
Phone: (+44-121)4361000
Fax: (+44-121)4307061
http://www.bindingsite.co.uk
info@bindingsite.co.uk
Company Contacts
Department/ Name Address
Herr Rolf Körner Tel: 49-6202-9262-116
rolf.koerner@bindingsite.de
Company Figures
Number of employees 100-499
Sales volume 10-49 Mio US $
Export content > 75%
Year of foundation 1984
Area of business Diagnostics
Language: German Language: English Company Profile
About Us
Our history
he origins of the company go back to the early 1960’s when antisera was produced to meet the needs of the Immunology Department within the University of Birmingham Medical School. The range of antisera produced was small but novel and of a very high quality, leading to numerous requests for material from immunology groups around the world. During the ensuing years the range of antibodies grew rapidly and in the early 1980’s a commercial immunodiagnostic company, The Binding Site, was founded.
Growth through innovation
Expertise in immunisation and processing techniques gained over the years within the University, and further honed as a commercial company, have enabled us to become a primary antibody manufacturer of world class standing. Polyclonal antibody manufacture is conducted in sheep on our own farms and the annual volume we produce is several thousand litres, both for our own use and as raw material for other manufacturers. The success of this core business has enabled us to build a range of immunodiagnostic products aimed at fulfilling the needs of clinical immunology laboratories, whatever their size or complexity. Despite being a fully independent commercial company we still retain close academic links with our University colleagues to ensure we are at the forefront of Immunology research. The fruits of this collaboration are shared with our customers world-wide. Innovative new products and improved product performance are the benefits of having this academic background coupled with a highly professional scientific and technical manufacturing staff.
Assays to aid clinicians and laboratories
Our product portfolio has grown to include not only the most comprehensive range of IgG subclass assays in the world, but also a significant range of autoimmune products utilising both
immunofluorescence and ELISA technologies. We have also been able to develop the Freelite assays, the first nephelometric tests for measuring free immunoglobulin light chains in serum. These assays give a sensitivity, accessibility and consistency never before achievable, allowing significant improvements in laboratory and clinical practice for the detection and monitoring of B cell malignancies.
Assurance of Quality
As a manufacturer of diagnostic products we understand the necessity of ensuring that the assays our customers use are always of the highest quality possible. As early as 1992 we gained IS09002 certification with IS09001 being gained in 1997. Currently we have certification for both IS09001 and IS013485 (this is a specialist quality system specifically for in vitro diagnostics). On top of this we have FDA clearance for those products sold for diagnostic use in the USA, our clinical products are CE marked for the majority of European countries and have been successfully registered by the regulatory authorities in many individual countries. These rigorous Quality Assurance procedures help ensure that we provide only products of the very highest standard. With technical support and educational programmes offered world-wide we are able to offer all of our customers the benefits of our technical expertise and knowledge.
Product Information
02.01 Analyser appliances
02.01.37 Nephelometers/ nephelometry
02.01.70 Turbidimeters / turbidimetry
03.01.03 Electrophoresis equipment
03.01.03.07 Gel electrophoresis
03.01.03.10 Immunoelectrophoresis
03.01.03.14 Reagents for electrophoresis
03.02.03 Auto-immune diseases
Freelite™ Serum Free Light Chain Assays 19.09.2007
Freelite is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia. There is now significant clinical evidence indicating the benefit of these assays in initial screening for monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional methods, for risk stratification of MGUS patients* and rapid evaluation of treatment efficacy.
Freelite assays were developed by The Binding Site to measure free lambda and free kappa immunoglobulin light chains. Our expertise in the manufacture of antibodies has enabled us to provide a quantifiable, highly specific, automatable free light chain assay for serum.
Summary of Data
Published data indicate that 100% of patients with Light Chain (Bence Jones) Multiple Myeloma1, 82% of patients with Nonsecretory Multiple Myeloma2, over 98% of patients with AL amyloidosis3 and 96% of Intact Immunoglobulin Multiple Myeloma patients4 have abnormal serum free light chain concentrations. This improvement in disease detection rates, and the superior utility of serum free light chains for disease monitoring, may obviate the need for urine free light chain tests in most patients with monoclonal plasma diseases.
Additionally, the serum free light chain ratio has been identified as a major new independent risk factor for progression of patients with MGUS to multiple myeloma or other related disorders5 *.
General information on the use of serum free light chains is available in a paper published in Clinical Laboratory International (CLI) in November 2003 and in a recent Clinical Chemistry editorial6.
Download CLI November 2003 Article as published in Clinical Laboratory International, November 2003. Click here to visit the CLI website.
03.02.03.02 Diagnostics / kits for the gastro enterology
03.02.03.03 Diagnostics / kits for the thyroid gland analyses
03.02.07 Immuno assay systems
03.02.07.06 Enzyme immunoassay (EIA, ELISA, EMIT)
03.02.07.20 Radial immunodiffusion (RID), rocket immunoelectrophoresis (electroimmunoassay, Laurell technique)
03.02.07.24 Substrate-labelled fluorescence immunoassay (SLFIA)
03.02.08 Units and systems for the determination of immunoglobulins and plasma proteins
03.02.08.01 Diagnostic agents / kits for immunoglobulin and plasma protein determination
03.02.08.03 Control material for immunoglobulin and plasma protein determination
03.02.08.04 Nephelometry
03.02.08.05 Reagents for immunoglobulin and plasma protein determination
03.02.08.06 Turbidimetry
03.02.08.07 Accessories for immunoglobulin and plasma protein determination
03.02.10 Controls / Standards / Calibrators immunochemistry
03.02.12 Rheumatoid diseases
03.02.12.01 Diagnostic agents / kits for diagnosis of rheumatism
03.02.12.03 Control material for diagnosis of rheumatism
03.02.14 Specific proteins
03.02.14.01 C-reactive proteins (CRP)
03.02.17 Tumor markers
03.02.17.01 Diagnostic agents / kits for tumour marker determination
03.05.01 Bacteriology - Infectious immunology
03.05.04 Controls / Standards / Calibrators - Infect. immunology
03.05.05 Equipment and systems for microbiological diagnosis/virology
03.05.05.01 Diagnostic agents / kits for microbiological diagnosis